Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 189-196

  Wason, Suman ^a   Digiacinto, Jennifer L ^b   Davis, Matthew W ^a  

^a URL Pharma Inc   (United States)

^b Salamandra LLC   (United States)

Author keywords

Colchicine; Cyclosporine; Drug interaction; Pharmacokinetics; Solid organ transplantation

Indexed keywords

COLCHICINE; CYCLOSPORIN; ANTIGOUT AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIURIA; CONTROLLED STUDY; CONTUSION; COUGHING; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SORE THROAT; THROAT IRRITATION; BLOOD; CLINICAL TRIAL; DRUG INTERACTION;

ADULT; COLCHICINE; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; GOUT SUPPRESSANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; YOUNG ADULT;

EID: 84871707292     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2579     Document Type: Article

References (40)

1. Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11(17):2933-2938.
2. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48(9):1153-1158.
3. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29(11):2403-2406.
4. Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.
5. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443-449.
6. Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: the National Health and Nutrition Examination Survey (NHANES) [abstract]. Arthritis Rheum. 2010;62(suppl 10):S2154.
7. Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383-1391.
8. Abdelrahman M, Rafi A, Ghacha R, Youmbissi JT, Qayyum T, Karkar A. Hyperuricemia and gout in renal transplant recipients. Ren Fail. 2002;24(3):361-367.
9. Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation. 2001;72(10):1689-1691.
10. Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005; 65(18):2593-2611.
11. Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5): 397-400.
12. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321(5):287-292.
13. Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation. 1991;52(1):64-67.
14. Delaney V, Sumrani N, Daskalakis P, Hong JH, Sommer BG. Hyperuricemia and gout in renal allograft recipients. Tranplant Proc. 1992;24(5):1773-1774.
15. Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141-146.
16. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl 1):S2.
17. Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984;77(4):652-656.
18. Mazzali M. Uric acid and transplantation. Semin Nephrol. 2005;25(1): 50-55.
19. Stamp L, Ha L, Searle M, O'Donnell J, Frampton C, Chapman P. Gout in renal transplant recipients. Nephrology (Carlton). 2006; 11(4):367-371.
20. Hernández-Molina G, Gachafeiro-Vilar A, Villa AR, Alberú J, Rull-Gabayet M. Gout in renal allograft recipients according to the pretransplant hyperuricemic status. Transplantation. 2008; 86(11):1543-1547.
21. Shohat M, Halpern GJ. Familial Mediterranean fever-a review. Genet Med. 2011;13(6):487-498.
22. Cohen SL, Boner G, Shmueli A, Yusim A, Rosenfeld J, Shapira Z. Cyclosporin: poorly tolerated in familial Mediterranean fever. Nephrol Dial Transplant. 1989;4(3):201-204.
23. Colcrys® (colchicine, USP) tablets for oral use [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company, Inc.; 2012. http://www.colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Informa-tion.pdf. March 14, 2012. Accessed April 25, 2012.
24. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226-2237.
25. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068.
26. US Food and Drug Administration. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInfor-mation/Guidances/ucm072101.pdf. 2006. Accessed February 21, 2012.
27. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/down-loads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf. 2012. Accessed February 21, 2012.
28. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562-1568.
29. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18(2):264-269.
30. Cook M, Ramos E, Peterson J, Croker B. Colchicine neuromyopathy in a renal transplant patient with normal muscle enzyme levels. Clin Nephrol. 1994;42(1):67-68.
31. Rieger EH, Halasz NA, Wahlstrom HE. Colchicine neuromyopathy after renal transplantation. Transplantation. 1990;49(6):1196-1198.
32. Tapal MF. Colchicine myopathy. Scand J Rheumatol. 1996; 25(2):105-106.
33. Rana SS, Giuliani MJ, Oddis CV Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg. 1997;99(4):266-270.
34. Wluka AE, Ryan PF, Miller AM, et al. Post-cardiac transplantation gout: incidence of therapeutic complications. J Heart Lung Transplant. 2000;19(10):951-956.
35. Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol. 2000;27 (6):1334-1337.
36. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol. 1992;43(1):109-117.
37. Gruberg L, Har-Zahav Y, Agranat O, Freimark D. Acute myopathy induced by colchicine in a cyclosporin treated heart transplant recipient: possible role of the multidrug resistance transporter. Transplant Proc. 1999;31(5):2157-2158.
38. Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology. 1992;15(5):899-903.
39. Speeg KV Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther. 1992;261(1):50-55.
40. Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant. 1997;12(11):2389-2392.